Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
· monte rosa therapeutics, inc.
AI Briefing
- Monte Rosa Therapeutics presents preclinical data at AACR 2026 on CCNE1-directed MGDs for CCNE1-amplified solid tumors.
- The treatment targets Cyclin E1 (CCNE1) amplification in solid tumors.
- AACR 2026 meeting highlights potential therapeutic approach.
Advertisement